Regentis Biomaterials Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RGNT NYSE American 2836 www.regentis.co.il

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Regentis Biomaterials Ltd.

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd. - Sep 18th, 2026 8:15 am
Regentis Biomaterials (RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair - Sep 14th, 2026 1:26 pm
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update - Sep 11th, 2026 7:00 am
Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC - Aug 28th, 2026 12:30 pm
Regentis Biomaterials (RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks - Aug 17th, 2026 12:16 pm
Regentis Biomaterials (RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market - Aug 14th, 2026 12:30 pm
Regentis Biomaterials (RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair - Aug 3rd, 2026 1:30 pm
Regentis Biomaterials (RGNT) Targets $3B Cartilage Repair Market with Cell-Free Gelrin C - Jul 30th, 2026 1:30 pm
Regentis Biomaterials (RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3B Cartilage Repair Market - Jul 27th, 2026 1:00 pm
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology - Jul 20th, 2026 7:00 am
Regentis Biomaterials (RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process - Jul 16th, 2026 9:30 am
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch - Jul 15th, 2026 7:00 am
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement - Jun 17th, 2026 7:05 pm
This Monthly Dividend Powerhouse Is Trading at a Bargain-Bin Valuation - Jun 16th, 2026 12:00 pm
Why Did RGNT Stock Surge More Than 850% Today? - Jun 15th, 2026 12:06 pm
Regentis Biomaterials (RGNT) Advances European Commercial Launch Plans for GelrinC - Jun 8th, 2026 1:30 pm
Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate - Jun 8th, 2026 6:32 am
Regentis Biomaterials (RGNT) Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones - Jun 1st, 2026 1:15 pm
Regentis Biomaterials (RGNT) Targets Major Gap in Knee Cartilage Repair Market with Off-the-Shelf Regenerative Implant - May 29th, 2026 1:15 pm
Regentis Biomaterials (RGNT) Is 'One to Watch' - May 28th, 2026 1:30 pm